Efforts Underway to Improve the Overall Disclosure Process
Minimizing 'Human Risk' by Expanding AI Utilization
"We Will Take Responsibility for Compensating Investor Losses"

On March 18, the Korea Exchange announced, regarding its mistaken removal of SCM Life Science from the management issue list, that it would "work to improve the overall disclosure process by introducing a cross-verification system for important disclosures and utilizing AI technology."


Exchange to Immediately Launch 'Market Action Council' Following Management Issue Delisting Error View original image

In a press release issued the same day, the Exchange stated, "To enable more prudent decision-making regarding important disclosures, we will immediately operate a 'Market Action Council' (tentative name) chaired by the executive in charge of disclosures and composed of division and team leaders." It added, "For disclosures involving market actions that have a significant impact on investors—such as the designation and removal of management issues and occurrences of delisting grounds—the Market Action Council will conduct thorough cross-verification before handling them."


In the mid- to long-term, the Exchange plans to review its entire existing disclosure system to identify risk factors, and to increase the use of artificial intelligence (AI) in the next-generation listing and disclosure system currently under development, in order to minimize the human risks inherent in the disclosure process.


The Exchange stated, "We will build a system where AI will make a preliminary determination on whether action is needed, after which a responsible person will verify and finalize the action." It continued, "With regard to the investor losses arising from this market action error, we will make investor protection our top priority and will bear all necessary responsibilities, promptly reviewing and implementing all required measures."



Previously, on March 16, the Exchange removed SCM Life Science from the management issue list, only to reverse the decision the following day and re-designate the company as a management issue. The Exchange explained that it mistakenly believed SCM Life Science had met the requirements for removal from the list based on its 2025 audit report. In order to be removed from the management issue list, a company must report a profit from continuing operations before corporate income tax (EBIT, or pre-tax profit). However, the Exchange incorrectly judged that the reason for designating the company as a management issue had been resolved because the pre-tax loss from continuing operations sharply decreased from 13 billion won in the previous year to 400 million won in the latest year, and the net profit turned positive.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing